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Abstract: (−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported
anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is
overexpressed in several human carcinomas. To improve the pharmacological profile of EGCG,
we previously developed a family of EGCG derivatives and the lead compounds G28, G37 and G56
were characterized in HER2-positive breast cancer cells overexpressing FASN. Here, diesters G28, G37
and G56 and two G28 derivatives, monoesters M1 and M2, were synthesized and assessed in vitro for
their cytotoxic, FASN inhibition and apoptotic activities in MDA-MB-231 triple-negative breast cancer
(TNBC) cells. All compounds displayed moderate to high cytotoxicity and significantly blocked FASN
activity, monoesters M1 and M2 being more potent inhibitors than diesters. Interestingly, G28, M1,
and M2 also diminished FASN protein expression levels, but only monoesters M1 and M2 induced
apoptosis. Our results indicate that FASN inhibition by such polyphenolic compounds could be a new
strategy in TNBC treatment, and highlight the potential anticancer activities of monoesters. Thus,
G28, G37, G56, and most importantly M1 and M2, are anticancer candidates (alone or in combination)
to be further characterized in vitro and in vivo.
Keywords: triple-negative breast cancer; fatty acid synthase; FASN inhibition; polyphenolic FASN
inhibitors; (−)-epigallocatechin 3-gallate; synthetic analogues; apoptosis; anticancer activity
1. Introduction
Breast cancer is the most widespread cancer in women worldwide [1]. Although mortality has
diminished in recent years owing to the programs of early diagnosis and to the improvement in
treatment, this disease is still the first cause of death in women. Triple-negative breast cancer (TNBC)
is a subtype of breast cancer in which the estrogen and the progesterone receptors are not expressed,
and the human epidermal growth factor receptor 2 (HER2) is not amplified or overexpressed [2–5].
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TNBC comprises about 15–20% of all breast cancers diagnosed. It tends to have an aggressive clinical
course and to metastasize, resulting in early relapse and poor overall survival [2]. Patients with TNBC
do not benefit from the targeted therapies used in other breast cancer subtypes, such as hormonal and
anti-HER2 receptor therapies, thus leaving systemic cytotoxic chemotherapy as the sole treatment
option [3–5]. The aggressiveness of this cancer and the scarcity of effective treatment options evidence
the need of developing new therapeutic agents.
Metabolism deregulation is considered a hallmark of cancer [6,7]. In this sense, some metabolic
enzymes such as fatty acid synthase (FASN) have been identified as valuable therapeutic targets
for cancer treatment [8]. FASN is a homodimeric multienzymatic protein responsible for de novo
fatty acid synthesis. It has a low or absent expression in normal tissues, but it is overexpressed and
hyperactivated in many carcinomas such as breast cancer [8,9]. This overexpression correlates with
a malignant phenotype and a poor disease prognosis. Therefore, the pharmacological inhibition of
FASN is recognized as an attractive therapeutic approach. Blocking FASN activity triggers apoptosis
in cancer cells and inhibits tumor growth in xenograft models [10], by disrupting lipid membrane
synthesis, protein palmitoylation, and signalling of major oncogenic pathways [11,12]. Remarkably,
FASN inhibition has minimal effect on non-malignant cells. Moreover, a recent study has shown that
FASN is expressed in TNBC patient samples and that TNBC preclinical models benefit from FASN
inhibition [13].
The most representative FASN inhibitors are cerulenin, its synthetic derivative C75, and orlistat [9,11].
Even though these compounds have proven effective at controlling the progression of breast cancer,
they have limitations that restrict their clinical development. These include chemical instability,
low bioavailability, and stimulation of carnitine palmitoyltransferase-1 (CPT-1), which causes the
acceleration of fatty acid β-oxidation and undesirable side effects such as body weight loss. On the
other hand, epigallocatechin-3-gallate (EGCG, Figure 1a), the main polyphenolic catechin of green tea,
has been described to inhibit FASN, to induce apoptosis in vitro and to reduce tumor size, without
parallel CPT-1 stimulation or weight loss [9,13–16]. Specifically, the antiproliferative effects of EGCG
have been widely reported in MDA-MB-231 TNBC cells [13,17–19], and such effects have also been
associated, besides to FASN inhibition, to β-catenin downregulation [17,20]. Nevertheless, EGCG
displays low potency, poor bioavailability, and limited stability in physiological conditions [21,22].
Considering this profile, EGCG’s structure inspired the design and synthesis of a novel collection
of polyphenolic compounds, containing two galloyl moieties (3,4,5-trihydroxybenzoyl group) linked
by a variable cyclic subunit (Figure 1b) [21,22]. The collection was screened for cytotoxicity and FASN
inhibition against a HER2-positive human breast cancer cell line overexpressing FASN, and three
lead compounds were identified, G28, G37, and G56 (Figure 1c), which improved the properties of
their precursor molecule EGCG without affecting mice body weight [21–23]. G28 has been the most
studied lead to date, proving effective in different HER2-positive breast cancer models, both in vivo
and in vitro [10,24], and recently in TNBC in vitro models [25]. In addition, in vivo pharmacokinetic
analyses have showed that G28 is hydrolyzed into two metabolites, M1 and M2 (Figure 1d) [23].
These compounds have already been tested for potential antibacterial activity [26] but, interestingly,
not for anticancer activity. The purpose of the current study was to assess FASN inhibition by synthetic
polyphenolic compounds as a potential therapeutic approximation for the clinically challenging TNBC.
We synthesized diesters G28, G37 and G56 together with G28-derived monoesters M1 and M2, and we
evaluated their cytotoxicity and capacity to inhibit FASN activity and to induce apoptosis in the
MDA-MB-231 TNBC cell model.
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with the conveniently protected acyl chloride derivative of gallic acid and the subsequent removal of 
the protecting groups. Diesters G28, G37 and G56 were obtained in 46, 65 and 61% overall yield, 
respectively, and monoesters M1 and M2 in 24 and 20% overall yield, respectively. All compounds 
were fully characterized by NMR and mass spectrometry. Additional NOESY and HMBC 
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The cytotoxic activity of G28, G37, G56 [21,22], M1 and M2 [26] was evaluated in the MDA-MB-
231 human TNBC cell line. The IC50 values of compounds were determined from their dose-response 
curves (Table 1). This line has lower constitutive FASN expression levels than the SK-Br3 HER2-
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Diesters G28, G37 and G56 were more cytotoxic than their parent molecule EGCG (IC50 = 149 µM 
[13]), in particular being 1.9-, 1.4- and 3.3-fold more potent respectively. Monoesters M1 and M2 turned 
out to inhibit cell proliferation. In comparison to their parent compound G28 (77 µM), M2 exhibited the 
same cytotoxic activity (79 µM) and, interestingly, M1 doubled such cytotoxicity (41 µM). 
  
Figure 1. Structures of (−)-epigallocatechin 3-gallate (EGCG) (a), EGCG derivatives (b), the lead
diesters (c) and the monoesters of G28 (d) [21,22,26].
2. Results
2.1. Synthesis of EGCG Analogues
The synthesis of diesters G28, G37 and G56 [21,22], and of monoesters M1 and M2 [26] was performed
using procedures adapted from previously described protocols (Supplementary Materials) [23,26,27].
The synthesis encompassed the esterification of the corresponding aromatic diol with the conveniently
protected acyl chloride derivative of gallic acid and the subsequent removal of the protecting groups.
Diesters G28, G37 and G56 were obtained in 46, 65 and 61% overall yield, respectively, and monoesters
M1 and M2 in 24 and 20% overall yield, respectively. All compounds were fully characterized by
NMR and mass spectrometry. Additional NOESY and HMBC experiments allowed the unambiguous
assignment of the regioisomeric monoesters M1 and M2.
2.2. Effect of EGCG Analogues on Cell Proliferation
The cytotoxic activity of G28, G37, G56 [21,22], M1 and M2 [26] was evaluated in the MDA-MB-231
human TNBC cell line. The IC50 values of compounds were determined from their dose-response
curves (Table 1). This line has lower constitutive FASN expression levels than the SK-Br3 HER2-positive
breast cancer cell line against which compounds were previously screened [21,22].
Diesters G28, G37 and G56 were more cytotoxic than their parent molecule EGCG
(IC50 = 149 µM [13]), in particular being 1.9-, 1.4- and 3.3-fold more potent respectively. Monoesters M1
and M2 turned out to inhibit cell proliferation. In comparison to their parent compound G28 (77 µM),
M2 exhibited the same cytotoxic activity (79 µM) and, interestingly, M1 doubled such cytotoxicity
(41 µM).
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Table 1. Cytotoxicity in MDA-MB-231 cancer cells of diesters and monoesters.
Compound IC50 (µM) a
EGCG 149.0 ± 6.7 b
G28 c 77.3 ± 3.4
G37 c 103.7 ± 1.9
G56 c 45.4 ± 3.4
M1 d 41.4 ± 1.5
M2 d 78.9 ± 4.6
a Data are mean ± SE from six independent experiments performed in triplicate. b Datum taken from [13].
c Compound described in [21,22]. d Compound described in [26].
2.3. Effect of EGCG Analogues on FASN Activity and on FASN Protein Expression
The capacity of G28, G37, G56 [21,22], M1 and M2 [26] to block FASN enzymatic activity in
MDA-MB-231 cells was analyzed after a 48-h treatment with a concentration equal to the IC50 value of
each compound. The inhibition is represented as the percentage of remaining activity with respect to
untreated cells (Figure 2). The previously reported FASN-specific inhibitor C75 (IC50 = 46.6 ± 2.2 µM
in MDA-MB-231 [13]) was used as a positive control.
Diesters G28, G37 and G56 significantly reduced FASN activity to 1.99 ± 0.27%, 2.39 ± 0.48%,
and 0.86 ± 0.20% of untreated (control, CTRL) cells, respectively (all p = 0.000), to an equivalent
extent as C75 (1.81 ± 0.39%). Monoesters M1 and M2, besides their cytotoxicity, were also able to
reduce FASN activity in an even more powerful way than their parent G28. M1- and M2-treated cells
displayed remaining FASN activities of 0.07 ± 0.01% and 0.04 ± 0.01%, respectively (both p = 0.000).
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C75 or with dimethyl sulfoxide (DMSO). FASN activity was assayed by counting radiolabelled fatty 
acids synthesized de novo. Bars represent the remaining activity as percentage in treated cells versus 
untreated (control, CTRL) cells considered 100% activity. Data are mean ± SE from at least 4 assay 
points per condition in 3 independent experiments. ***, P < 0.001 versus control cells (DMSO). #, P < 
0.05; ####, P < 0.001 versus C75-treated cells. Statistics were performed through Student’s t-test. 
In parallel, in order to check whether the observed FASN activity decrease was related to 
changes in FASN protein levels, cells were treated with diesters and monoesters as described in the 
i re 2. G28, G37, G56 [21,22], M1 and M2 [26] inhibit fatty acid synthase (FASN) activity in
DA-MB-231 TNBC cells. Cells were treated for 48 with an IC50 concentration of 28, 37, G56, 1,
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#, p < 0.05; ####, p < 0.001 versus C75-treated cells. Statistics were performed through Student’s t-test.
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In parallel, in order to check whether the observed FASN activity decrease was related to changes
in FASN protein levels, cells were treated with diesters and monoesters as described in the next
Section 2.4 and FASN expression was analyzed by Western blot (Figure 3a). G37 and G56 did not
modulate FASN protein levels, whereas G28 and its derivatives M1 and M2 displayed a tendency to
reduce such levels (Figure 3b), which was more noticeable for M2.
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2.4. Effect of EGCG Analogues on Apoptosis
Our group previou ly reported in SK-Br3 c lls the ctivation of the ap ptotic cell eath
mechanism by EGCG and its new-generation derivatives [14–16,21,22]. Accordi gly, diesters [21,22]
and m noe ters [26] were evaluated in MDA-MB-231 cells for their ability to induce caspase activity,
which causes cleavage of poly(ADP-r bose) polymerase (PARP). Cells were incubated for 24 h with
concentrations corresponding to five-fol t IC50 values of G28, G56, 1 and M2, and two-fold the
IC50 value of G37, because of the mortality induced by G37 at higher IC50 multiples (d ta not shown).
PARP cl avage was analyzed by Western blot (Figure 3a). Apoptosis induction wa not detected nder
the assayed conditions for any of the three diesters G28, G37 and G56. In ontrast and interestingly,
it was detected for both monoesters M1 and M2, with M2 showing a more intense band of cl aved
PARP (89 kDa).
3. Discussion
TNBC is an aggressive cancer lacking a targeted therapy [3–5]. FASN is overexpressed in a variety
of human carcinomas [8,9], including TNBC [28], and its inhibition with polyphenolic compounds
such as EGCG has been demonstrated to be a promising therapeutic strategy, alone and in combination,
for TNBC [13]. In this study, we characterized the anticancer effects of the EGCG analogues G28, G37
and G56 [21,22], and the G28 derivatives M1 and M2 [26], in MDA-MB-231 cells.
Firstly, the cytotoxic activity of compounds was determined. Diesters G28, G37 and G56 [21,22]
displayed moderate IC50 values of 77, 104 and 45 µM, respectively, at 48-h exposure. Our group
has studied the reference FASN inhibitors C75 and EGCG in several cancer cell lines, including
MDA-MB-231 [13], in which the IC50 values were 46.6 ± 2.2 and 149.0 ± 6.7 µM, respectively. Thus,
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the three diesters are more potent than their parent molecule, as reported in SK-Br3 cells, and G56 is
equally potent to C75. On the other hand, from the initial screening of EGCG analogues in SK-Br3 cells,
some structure-activity relationships were inferred [22]. One of them was that cytotoxicity increases
as the distance between the two galloyl moieties augments within the cyclic subunit. This could
explain the superior cytotoxicity of G56, in which galloyl groups are in a relative 4,4′-position within
a biphenyl system, further from each other than in the naphthalene ring of G28 and G37 (Figure 1c).
Concerning monoesters M1 and M2 [26], which are metabolites of G28 in physiological conditions [23],
they proved cytotoxic in MDA-MB-231 cells. M2 (IC50 = 79 µM) retained the activity of G28 while M1
(41 µM) enhanced that activity. This result raised the possibility that the in vivo antitumor efficacy of
G28 is due, at least partially, to the two monoesters.
Beyond the obtained results, a positive correlation between the cytotoxic effects of the
aforementioned inhibitors and cellular FASN expression has been reported [14,21–23], from the
observation that compounds are less potent in MDA-MB-231 triple-negative cells, with low FASN
levels, than in SK-Br3 HER2-positive cells, with high FASN levels. To support the correlation, it was
demonstrated that the addition of exogenous palmitate, the end product of FASN, reduced the
cytotoxicity of EGCG [14], and that the knockdown of FASN suppressed the cytotoxicity of G56 [22].
Hence, FASN inhibition plays a major role in the cytotoxicity of these polyphenolic compounds.
Secondly, the ability of the tested compounds [21,22,26] to block FASN activity was tackled.
Compounds, at 48-h exposure, exerted a significant FASN activity reduction of 98.0%, 97.6% and 99.1%
for diesters G28, G37 and G56, and of 99.93% and 99.96% for monoesters M1 and M2, respectively,
as measured by an enzymatic radioassay. Moreover, G28 and its derivatives M1 and M2 also reduced
FASN protein levels, unlike G37 and G56. Therefore, the observed FASN activity decrease in G28,
M1 and M2 lysates could probably result not only from enzyme inhibition but also from diminished
amounts of FASN protein. Our results show that, as for diesters [21,22], G56 is a more potent FASN
inhibitor than G37 and G28, assuming that for G28 the remaining activity could be slightly higher in the
absence of FASN downregulation (Figure 2). On the other hand, G28 stands out as the most effective
diester due to its dual effect on FASN (activity and expression). Regarding monoesters [26], M1 and
M2 affect FASN protein levels to a similar extent as G28 (Figure 3b) but, remarkably, both are better
FASN inhibitors than G28 (Figure 2). These results indicate that the affinity for FASN of monoesters is
greater than that of their parent molecule, being probably similar between the two monoesters.
In the original characterization, FASN inhibition values in SK-Br3 cells at 24-h exposure were
90 ± 4%, 69 ± 19% and 90 ± 5% for G28, G37 and G56, and 18% for EGCG, as measured
by spectrophotometry, and FASN inhibition was not accompanied by downregulation of FASN
expression [21,22]. These data evidence that diesters inhibit FASN more effectively than their parent
molecule and agree with our results that G37 seems to be the less potent inhibitor. The observed FASN
downregulation by G28 in MDA-MB-231 but not in SK-Br3 could be attributable to the concentration
used, which was five-fold the IC50 value in our treatments against one-fold the IC50 value in the
literature. Anyway, FASN downregulation has also been reported elsewhere, by C75 in A2780 ovarian
cancer cells in a dose-dependent manner [29], and by EGCG, in A549 lung cancer cells [16] and in
chemo-sensitive and -resistant MDA-MB-231 and HCC1806 TNBC cells [13]. A possible mechanism for
this downregulation is that G28, apart from inhibiting FASN, could to some extent also inhibit the EGF
receptor (EGFR), which is overexpressed in TNBC [30], thus impairing the downstream signalling that
ends in FASN expression. This effect could occur at the transcriptional level, through PI3K and MAPK
pathways activating the transcription factor SREBP-1c [31]; and at the translational level, through
mTOR protein activating eIF4E and S6K [32]. Finally, FASN downregulation by monoesters M1 and
M2 [26] is consistent with the result obtained for their parent molecule.
Beyond our results, in parallel to FASN inhibition and downregulation, EGCG and
other polyphenols such as quercetin have also been described to reduce β-catenin protein
expression [17,20,33,34]. β-catenin, when bound to E-cadherin complexes, functions as a cell-cell
adhesion molecule, but when translocated to the nucleus acts as a key element in the Wnt signalling
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pathway, activating the transcription of target genes related to cell proliferation and metastasis, thus
contributing to breast cancer progression [17,33]. Therefore, forthcoming studies in our group will
investigate whether diesters and monoesters are able to modulate β-catenin expression and its nuclear
accumulation in TNBC.
This is the first study testing monoesters M1 and M2 as potential anticancer agents. However, both
monoesters have already been tested in another setting, as synthetic inhibitors of bacterial cell division
targeting the GTP-binding site of protein FtsZ [26]. In that study, the affinity for FtsZ of monoesters,
competing with GTP, was one order of magnitude lower than that of diester G28, with the affinity of M2
being slightly higher than that of M1, as determined by Kb comparison. The affinity of EGCG was two
orders of magnitude lower relative to that of G28. Thus, only G28 was included in further biochemical,
structural and antibacterial characterization. In striking contrast, our results suggested that the
affinity for FASN is larger for monoesters than for G28. Aiming to understand this differential affinity,
a future perspective of our group will be to gain insights, through molecular docking analyses, in the
potential binding modes of G28 and monoesters to their target FASN catalytic domains. These domains
are probably the same as those targeted by EGCG, the NADPH-dependent domains ketoreductase
(KR) [35] and enoyl reductase (ER) [36–39], which participate in the saturation of the growing fatty
acid chain [40]. Interestingly, EGCG has been shown to compete with NADPH/NADH for binding to
KR and ER [35–39]. Since both NADPH/NADH (FASN) and GTP (FtsZ) are nucleotides, it is worth
noting that, in the FtsZ study, the galloyl groups and the naphthalene scaffold of G28 were predicted
to replace the interactions by the phosphates and the nucleobase of the nucleotide, respectively [26].
This could also be true in the interaction of G28 with FASN.
Thirdly, the capacity of compounds [21,22,26] to activate apoptotic cell death was addressed.
The superior activity of monoesters was reaffirmed since, at 24-h exposure, monoesters, more
importantly M2, induced PARP cleavage whereas diesters did not have this effect, despite using
IC50 multiples as concentration. In the original characterization of diesters in SK-Br3 cells, an IC50
concentration value was sufficient to perceive truncated PARP as early as 12 h [21,22]. An equal result
was obtained for C75 and EGCG in SK-Br3 and A549 cells [14,16], and for EGCG in chemo-sensitive
and -resistant MDA-MB-231 and HCC1806 cells [13]. In addition, apoptosis has also been reported for
EGCG combined with cetuximab in TNBC xenograft models [13]; and for G28, in other HER2-positive
breast cancer models both in vivo and in vitro, alone and combined with anti-HER drugs [10], and in
several ovarian cancer models in a dose-dependent manner [41,42].
Considering the effect of EGCG and diesters in SK-Br3, it is surprising that only EGCG shows
effect in MDA-MB-231. The above described correlation between cytotoxicity and cellular FASN levels
implies that MDA-MB-231 cells are less reliant on FASN activity than SK-Br3 cells for their survival
and aggressiveness. Then, a possible hypothesis is that inhibition of FASN activity and expression
by diesters in MDA-MB-231 may not be enough to compromise cell survival and reach the threshold
for apoptosis induction, a threshold that may be comparatively lower in SK-Br3. In contrast, the two
monoesters have larger affinities for FASN than those of diesters and both affect FASN expression, thus
being able to overcome the threshold in MDA-MB-231. On the other hand, EGCG has been described to
bind targets other than FASN [43]. Therefore, it may induce apoptosis through FASN inhibition along
with other mechanisms, and so apoptosis may be detected irrespective of the cellular dependence
on FASN.
In summary, in this study we evaluated the previously described G28 derivatives M1 and M2 [26]
for first time as anticancer agents and partially disclosed their pharmacological profile in a TNBC
model. Monoesters M1 and M2 turned out to be equally or more cytotoxic and to have a larger
affinity for FASN than their parent molecule, to affect FASN expression and to induce apoptosis,
which suggests that they could individually contribute to the in vivo antitumor activity of G28 after it
has been hydrolyzed. In order to confirm this hypothesis, a future decisive study will be conducted
to compare the efficacy of each monoester with that of G28 in a TNBC xenograft model. On the
other hand, in the same in vitro model, the previously designed EGCG-derived diesters G28, G37
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and G56 [21,22] exhibited cytotoxicity and remarkable FASN inhibition. Diesters, and especially
monoesters, hold promise as target-directed anticancer drugs, either alone or in combination, focused
on TNBC treatment. Furthermore, this work constitutes a starting point in our group for the future
synthesis and evaluation of other polyphenolic compounds, such as the monoesters of G37 and G56,
or computationally optimized compounds derived from the three diesters.
4. Materials and Methods
4.1. Cell Culture
MDA-MB-231 breast carcinoma cells were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). Cells were routinely grown in two-dimensional adherent conditions in
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Waltham, MA, USA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, 1% sodium pyruvate, 50 U/mL penicillin
and 50 µg/mL streptomycin (HyClone Laboratories, Logan, UT, USA). Cells were maintained at 37 ◦C
in a humidified atmosphere of 95% air and 5% CO2. The absence of Mycoplasma in cultures was
checked before experiments.
4.2. Inhibition of Cell Proliferation
Dose-response experiments were done by means of the standard colorimetric MTT
(3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) reduction assay. Cells were plated
out at a density of 4 × 103 cells/well in 96-well microtiter plates and were incubated overnight for
attachment. Then, cells were exposed for 48 h to fresh medium containing a range of concentrations of
the corresponding EGCG derivative (10–140 µM) or were exposed to fresh medium alone. An influence
of the vehicle dimethyl sulfoxide (DMSO) in the cytotoxicity of compounds was discarded. Following
treatment, cells were incubated for 3 h with drug-free medium (100 µL/well) and 5 mg/mL MTT
solution (Sigma-Aldrich, St. Louis, MO, USA; 10 µL/well). The formazan crystals formed by
metabolically viable cells were solubilized in DMSO and their absorbance (Abs) was measured at
570 nm (Benchmark Plus microplate spectrophotometer, Bio-Rad Laboratories, Hercules, CA, USA).
Using test (T) and control (C) average Abs values, the percentage of cell proliferation inhibition (CPI)
at each concentration was calculated from the formula CPI = 100(1−T/C). By interpolation in the
trendline of the resulting data points, the compound concentration that triggered 50% CPI (IC50 value)
was determined. The assay was performed six times per compound.
4.3. Inhibition of Fatty Acid Synthase Activity
Cells were plated out at a density of 5 × 104 cells/well in 24-well plates. Following overnight
cell adherence, the medium was replaced by DMEM supplemented with 1% lipoprotein-deficient FBS
(Sigma-Aldrich) along with the corresponding concentrations of compounds or DMSO. Treatments
were maintained for 48 h, and for the last 6 h (1,2-14C) Acetic Acid Sodium salt (53.9 mCi/mmol,
Perkin Elmer Biosciences, Waltham, MA, USA) was added to the medium (0.5 µCi/mL). The lipid
extraction was done as previously described in [16]. Briefly, cells were harvested and washed twice with
phosphate-buffered saline (PBS, HyClone Laboratories, Logan, UT, USA) and once with MeOH/PBS
(2:3). Cells were then resuspended in 0.2 M NaCl and were lysed with freeze-thaw cycles. Lipids from
cell debris were extracted with CHCl3/phenol (2:1) and 0.1 M KOH, and the organic phase was washed
with CHCl3/MeOH/H2O (3:48:47). After solvents evaporation, pellets were resuspended in EtOH and
transferred to a vial for radioactive counting. The total protein content in cell debris was quantified by
the Bradford assay (Sigma-Aldrich).
4.4. Immunoblot Analysis of Cell Lysates
After a 24-h exposure to the corresponding EGCG derivative or DMSO, culture appearance was
observed under microscope and cells were harvested by treatment with trypsin-ethylenediaminetetraacetic
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acid (EDTA) solution (Linus, Cultek, Madrid, Spain), together with supernatant cell debris. Cells plus
debris were washed with PBS and lysed in ice-cold lysis buffer (Cell Signaling Technology, Danvers,
MA, USA) supplemented with 2 mM phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich) by
vortexing every 5 min for 30 min. Particle-free lysates were obtained and their total protein content
was determined by the Lowry-based DC Protein Assay (Bio-Rad Laboratories). Lysates’ equal protein
amounts (30 µg) were heated in LDS Sample Buffer with Sample Reducing Agent (Invitrogen, Waltham,
MA, USA) for 10 min at 70 ◦C, were run on sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE, 7.5% polyacrylamide) and were transferred onto nitrocellulose membranes (Thermo
Scientific, Pierce Protein Biology, Waltham, MA, USA). Blots were incubated for 1 h at room temperature
in blocking buffer [5% powdered skimmed milk in tris-buffered saline with Tween 20 (TBST; 10 mM
Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween 20)] to avoid non-specific antibody binding. Then, blot
fragments were incubated overnight at 4 ◦C with the appropriate primary antibody diluted in blocking
buffer. Primary antibodies were rabbit polyclonal antibodies against FASN (Assay Designs, Ann Arbor,
MI, USA; 905-069; dilution 1:1500) and PARP (Cell Signaling Technology; #9542; dilution 1:1000),
and the mouse monoclonal antibody against β-actin (Cell Signaling Technology; #3700; dilution
1:2500). β-actin was used as a control of protein loading and transfer. Next, blots were washed in
TBST and were incubated for 1 h at room temperature with the corresponding horseradish peroxidase
(HRP)-conjugated goat secondary antibody diluted in blocking buffer, against rabbit (Cell Signaling
Technology; #7074; dilution 1:4000) or mouse (Merck Millipore, Darmstadt, Germany; #401215; dilution
1:5000) antibodies. Lastly, blots were washed again and revealed (ChemiDoc MP Imaging System,
Bio-Rad Laboratories) employing a chemiluminescent HRP substrate [Immobilon Western (Merck
Millipore) or SuperSignal West Femto (Thermo Scientific, Pierce Protein Biology)]. The immunoblot
analysis for each compound was repeated two or three times and a representative result is shown.
FASN and β-actin bands were quantified using ImageJ software (version 1.51j8, National Institutes of
Health, Bethesda, MD, USA).
4.5. Statistical Analysis
All data are expressed as mean ± standard error (SE). FASN inhibition data were analyzed
by Student’s t-test and levels of statistical significance were p < 0.001 (***) versus control cells,
and p < 0.05 (#), p < 0.001 (####) versus C75-treated cells.
Supplementary Materials: The following are available online, Synthesis of EGCG analogues.
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